Hospital Stocks Had a Rough Session. But What Now

Pharmacy mark-ups in question, cash-patient earnings mostly insulated, radio-pharmaceutical handling costs explaining the headline, insurance package rates buffering the hit, what’s in store for hospital stocks now?

India’s hospital sector is working through a regulatory scare that analysts have been bracing for since the DPCO cycle of 2013 — and the Supreme Court’s observations on 29 September on private hospital drug mark-ups are the latest flashpoint.

The sector — operators of corporate hospital chains across India’s tier-one and tier-two cities — delivered a trading session on 30 September that erased ₹24,800 crore of market value, with the BSE Hospitals Index falling around 5 per cent and 16 of its 17 members closing lower.

The Session 

The reaction across hospital names on 30 September was broad and sharp. Fortis Healthcare fell around 6 per cent, Apollo Hospitals dropped 5.95 per cent, KIMS declined 5.7 per cent, and Max Healthcare lost 5.3 per cent.

The BSE Hospitals Index closed roughly 5 per cent lower, with 16 of its 17 constituents in the red — a near-uniform sell-off that reflected sector-wide repricing of regulatory risk rather than any name-specific concern.

The Court cited an example of an oncology drug procured at approximately ₹2,700 but carrying a maximum retail price of ₹27,000 — a ten-fold mark-up at the patient end — and asked the Centre why the 16 per cent trade margin cap already applied to scheduled drugs under the Drugs (Prices Control) Order, 2013 has not been extended to the remaining 82 per cent of drugs classified as non-scheduled. The Centre has sought time to present data, with the next hearing scheduled for 12 October.

The Pharmacy Reality 

The headline mark-up cited by the Court is dramatic — but Emkay’s note contextualises why it is also unrepresentative.

Pharmacy mark-ups across the broader hospital business operate in a 20 to 25 per cent margin range, with select categories, notably radio-pharmaceuticals used in oncology treatment, appearing to carry substantially higher mark-ups on the invoice. “Our channel checks with hospital chains suggest that while certain cases where pharmacy mark-ups appear substantial (radio-pharmaceuticals), overall margins in the pharmacy business are in the 20-25% range,” the report states.

Radio-pharmaceuticals sit in a regulatory and operational category of their own. Handling is governed by the Atomic Energy Regulatory Board, with only licence holders permitted to supply.

The radioactive isotopes inside carry shelf lives as short as 30 to 100 minutes, meaning each dose must either be administered within that narrow window or discarded entirely. Factoring in that wastage, the realised cost to the hospital is substantially higher than the invoice value. “This, in turn, drives the hospital’s effective handling and procurement cost to 6-8x the headline invoice price,” the report notes.

The Insurance Buffer 

One of the structural features of the Indian hospital business model that the sell-off appears to have ignored is the composition of the patient base.

A significant share of revenue at listed hospital chains comes from insurance-covered and public health scheme patients, who are billed on pre-negotiated package rates rather than on headline MRPs.

Any margin cap on non-scheduled drugs, if it were to come, would primarily affect the cash-paying patient segment — a slice of the business, not the whole.

“This margin cap is likely to affect cash-patient margins, as insurance and public health schemes patients already take recourse of pre-negotiated package rates (discounted rack rates vs tariffs) rather than headline MRPs, thus further insulating hospital chains from any significant earnings hit, in our view,” the report notes.

In other words, the structural insulation already built into the hospital revenue mix means the earnings impact of a regulatory outcome — even an adverse one — would be meaningfully narrower than the sector-wide 5 per cent fall suggests.

The Regulatory Overhang 

The brokerage does not expect a wholesale extension of the 16 per cent margin cap across the entire non-scheduled drug universe. The operational complexity of applying such a cap across pharmaceutical manufacturers, distributors and the supply chain is a meaningful barrier to blanket implementation.

“We do not expect a blanket cap on drug margins as such, given the executional/operational challenges in covering non-scheduled drugs across ecosystems (pharma, distributor, supply-chain companies),” the report states.

Even so, the brokerage is clear-eyed that the sector will continue to carry a regulatory overhang. “Notably, though, the regulatory overhang on the sector, in some form or another, remains, given the socio-economic impact the sector is inherently exposed to,” the report notes. For investors, this is a reminder that hospital stocks will trade with higher headline sensitivity between now and the next hearing — and likely beyond.

Nevertheless, what will be the earnings impact of any eventual regulation? Emkay Global said, “Based on our discussions with hospital chains, we see limited impact on earnings for our Healthcare universe, as pharmacies contribute 15-20% of the overall revenue, along with a margin profile of 20-25%.”

The Coverage 

The brokerage retains BUY ratings on KIMS and Park Medi World, where valuation and growth converge most attractively, and ADD ratings on Medanta, Max Healthcare and Rainbow Children’s Medicare. The Q1FY27 fundamentals and expansion pipelines across these names remain intact. “We retain our rating/TP on KIMS (BUY/Rs850), Park (BUY/Rs375), Medanta (ADD/Rs1,500), Max HC (ADD/Rs1,150), and Rainbow (ADD/Rs1,550),” the report states.

Scorecard

Park Medi World offers the highest implied upside at 37 per cent to Emkay’s target of ₹375, followed by Max Healthcare at 24 per cent and Rainbow Children’s Medicare at 18 per cent.

admin